Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's Diarrhea

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1221-1224

  Fritsche, Thomas R ^a   Biedenbach, Douglas J ^a   Jones, Ronald N ^a,b,c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The JONES Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DOXYCYCLINE; DRUG METABOLITE; ERYTHROMYCIN; NALIDIXIC ACID; PRULIFLOXACIN; RIFAXIMIN; ULIFLOXACIN; UNCLASSIFIED DRUG;

AEROMONAS; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CAMPYLOBACTER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ESCHERICHIA COLI; GASTROENTERITIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLESIOMONAS; PRIORITY JOURNAL; SALMONELLA; SHIGELLA; TRAVELLER DIARRHEA; VIBRIO; YERSINIA;

ANTI-BACTERIAL AGENTS; DIARRHEA; DIOXOLANES; FLUOROQUINOLONES; GASTROENTERITIS; GRAM-NEGATIVE BACTERIA; HUMANS; PIPERAZINES; POPULATION SURVEILLANCE; PRODRUGS;

EID: 62949084685     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01260-08     Document Type: Article

References (18)

1. Adachi, J. A., L. Ostrosky-Zeichner, H. L. DuPont, and C. D. Ericsson. 2000. Empirical antimicrobial therapy for traveler's diarrhea. Clin. Infect. Dis. 31:1079-1083.
2. Araake, M., T. Hara, H. Watabe, and T. Nishino. 2002. In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone. Jpn. J. Antibiot. 55:778- 790.
3. Carmignani, G., A. F. De Rose, L. Olivieri, E. Salvatori, M. T. Rosignoli, and P. Dionisio. 2005. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol. Int. 74:326-331.
4. Cazzola, M., E. Salvatori, P. Dionisio, and L. Allegra. 2006. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Pulm. Pharmacol. Ther. 19(Suppl. l):30-37.
5. Clinical and Laboratory Standards Institute. 2006. M7-A7. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2006. M45-A. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2008. M100-S18. Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Clinical and Laboratory Standards Institute. Wayne, PA.
8. Giannarini, G., A. Mogorovich, F. Valent, G. Morelli, M. De Maria, F. Manassero, F. Barbone, and C. Selli. 2007. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J. Chemother. 19:304-308.
9. Gualco, L., A. M. Schito, G. C. Schito, and A. Marchese. 2007. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. Int. J. Antimi- crob. Agents 29:679-687.
10. Guerrant, R. L., T. Van Gilder, T. S. Steiner, N. M. Thielman, L. Slutsker, R. V. Tauxe, T. Hennessy, P. M. Griffin, H. DuPont, R. B. Sack, P. Tarr, M. Neill, I. Nachamkin, L. B. Reller, M. T. Osterholm, M. L. Bennish, and L. K. Pickering. 2001. Practice guidelines for the management of infectious diarrhea. Clin. Infect. Dis. 32:331-351.
11. Keam, S. J., and C. M. Perry. 2004. Prulifloxacin. Drugs 64:2221-2234.
12. Matera, M. G. 2006. Pharmacologic characteristics of prulifloxacin. Pulm. Pharmacol. Ther. 19(Suppl. l):20-29.
13. Montanari, M. P., L. Ferrante, E. Tili, I. Cochetti, V. Rossi, and P. E. Varaldo. 2005. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin. J. Chemother. 17:138-142.
14. Montanari, M. P., M. Mingoia, and P. E. Varaldo. 2001. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob. Agents Chemother. 45: 3616-3622.
15. Prats, G., C. Roig, E. Miro, F. Navarro, and B. Mirelis. 2002. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. 21:328-334.
16. Prats, G., V. Rossi, E. Salvatori, and B. Mirelis. 2006. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev. Anti-lnfect. Ther. 4:27-41.
17. Roveta, S., A. M. Schito, A. Marchese, and G. C. Schito. 2005. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aemginosa. Int. J. Antimicrob. Agents 26:366-372.
18. Steffen, R., D. A. Sack, L. Riopel, Z. D. Jiang, M. Sturchler, C. D. Ericsson, B. Lowe, P. Waiyaki, M. White, and H. L. DuPont. 2003. Therapy of travelers' diarrhea with rifaximin on various continents. Am. J. Gastroenterol. 98:1073-1078.